Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat

• Published in: The European journal of neuroscience Vol. 23; no. 7; pp. 1757 - 1765
• Main Authors: Freret, Thomas, Valable, Samuel, Chazalviel, Laurent, Saulnier, Romaric, Mackenzie, Eric T., Petit, Edwige, Bernaudin, Myriam, Boulouard, Michel, Schumann-Bard, Pascale
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2006; Wiley
• Subjects: Animals; Behavior, Animal - drug effects; Brain - drug effects; Brain - pathology; Brain - physiopathology; Deferoxamine - administration & dosage; Deferoxamine - pharmacology; Deferoxamine - therapeutic use; desferrioxamine; Hypoxia-Inducible Factor 1, alpha Subunit - biosynthesis; hypoxia-inducible factor-1; Infarction, Middle Cerebral Artery - complications; Iron Chelating Agents - administration & dosage; Iron Chelating Agents - pharmacology; Iron Chelating Agents - therapeutic use; Ischemic Attack, Transient - drug therapy; Ischemic Attack, Transient - etiology; Ischemic Attack, Transient - physiopathology; Life Sciences; Male; Motor Activity - drug effects; Neurons and Cognition; Rats; Rats, Sprague-Dawley; sensorimotor deficit; Brain; Cerebral Arteries; Oxygen; Animals; Erythropoietin; Genes; Rats; Glucose; Arteries; Middle Cerebral Artery; Stress
• ISSN: 0953-816X; 1460-9568
• DOI: 10.1111/j.1460-9568.2006.04699.x

The mechanisms underlying functional recovery after stroke are poorly understood. Brain‐adaptive responses to the hypoxic stress elicited by ischemia could contribute to these mechanisms. Indeed, hypoxia‐inducible factor‐1 (HIF‐1), one of the main transcriptional factors regulated by oxygen level, increases the expression of several beneficial genes such as erythropoietin, glucose transporter‐1 and vascular endothelial growth factor. In order to strengthen the expression of these hypoxia‐inducible factors, we administered deferoxamine, an iron chelator known to stabilize HIF‐1α protein expression, and examined its effects on the functional deficits induced by ischemia. Anesthetized Sprague–Dawley rats were subjected to 60 min of intraluminal occlusion of the middle cerebral artery. Chronic deferoxamine treatment (300 mg/kg, s.c.), or its vehicle, started 24 h after ischemia and was continued bi‐weekly until the animals were killed. Sensorimotor deficits were periodically assessed over 2 months, and at this end point, the lesion volume was determined by histology. Treatment with deferoxamine significantly decreased the size of brain damage (−28%) after ischemia and improved behavioral recovery. Indeed, neurological score and sensorimotor performances in the adhesive removal test recovered earlier in the deferoxamine‐treated animals. Moreover, the long‐lasting skilled forepaw reaching deficits were attenuated by deferoxamine. Although an antioxidant effect of deferoxamine cannot be excluded, the hypothesis that its beneficial effects could be mediated by an increase in HIF‐1 target genes merits further investigations. Our data suggest that delayed administration of deferoxamine could represent an interesting therapeutical approach to treat focal cerebral ischemia.